Amedisys, Inc. (NASDAQ:AMED) Holdings Lowered by JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered its stake in Amedisys, Inc. (NASDAQ:AMED) by 4.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 84,329 shares of the health services provider’s stock after selling 4,307 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.26% of Amedisys worth $8,139,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. KBC Group NV purchased a new stake in shares of Amedisys in the third quarter worth approximately $63,000. Signaturefd LLC lifted its position in Amedisys by 20.9% in the 3rd quarter. Signaturefd LLC now owns 1,367 shares of the health services provider’s stock worth $132,000 after buying an additional 236 shares in the last quarter. CWM LLC boosted its stake in shares of Amedisys by 14.5% during the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock valued at $211,000 after buying an additional 277 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of Amedisys during the 3rd quarter valued at $243,000. Finally, Intech Investment Management LLC purchased a new position in shares of Amedisys during the 2nd quarter valued at $280,000. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Amedisys Price Performance

Shares of NASDAQ:AMED opened at $91.98 on Wednesday. The firm has a market cap of $3.01 billion, a price-to-earnings ratio of 36.50, a P/E/G ratio of 1.84 and a beta of 0.72. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $89.42 and a 200 day simple moving average of $94.44.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 earnings per share for the quarter, missing analysts’ consensus estimates of $1.19 by ($0.19). The firm had revenue of $587.67 million for the quarter, compared to analysts’ expectations of $586.75 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same period last year, the business earned $0.98 earnings per share. As a group, sell-side analysts predict that Amedisys, Inc. will post 4.45 earnings per share for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.